Fas Expression on AIDS-PCNSL and EBV-LPD
| Tumor Specimen . | Samples* . | Expression . | Method . |
|---|---|---|---|
| AIDS-PCNSL | 2/2 | +++ | FACS |
| AIDS-PCNSL | 6/6 | +++ | IHC |
| hu-PBL-SCID EBV-LPD | 4/4 | +++ | FACS |
| hu-PBL-SCID EBV-LPD | 6/6 | +++ | IHC |
| hu-PBL-SCID LCLs | 18/18 | +++ | FACS |
| Tumor Specimen . | Samples* . | Expression . | Method . |
|---|---|---|---|
| AIDS-PCNSL | 2/2 | +++ | FACS |
| AIDS-PCNSL | 6/6 | +++ | IHC |
| hu-PBL-SCID EBV-LPD | 4/4 | +++ | FACS |
| hu-PBL-SCID EBV-LPD | 6/6 | +++ | IHC |
| hu-PBL-SCID LCLs | 18/18 | +++ | FACS |
Abbreviations: +++, 90%-100% reactive by FACS or IHC; FACS, fluorescence activated cell sorting; IHC, immunohistochemical analysis; hu-PBL-SCID EBV-LPD, SCID mouse engrafted with human peripheral blood lymphocytes with evidence of human EBV+ B-cell tumors; LCLs, lymphoblastoid cell lines derived from hu-PBL-SCID mice with EBV-LPD.
Number of samples testing positive/total number of samples analyzed.